Category: Uncategorized

May 4, 2015 – With extensive experience guiding biotech companies in matters including corporate development and clinical strategy, Dr. Garceau’s appointment strengthens Fluorinov’s leadership team and adds significant regulatory expertise as Fluorinov transitions to clinical development.

July 14, 2014 – BDC Capital joined as a new investor and Dion Madsen, Senior Managing Partner at BDC Capital, will join Xagenic’s Board of Directors.

May 28, 2014 – XLV, a MaRS Innovation start-up company based in Thunder Bay, closed a $3 million Series A investment round with Boston-based Bernard M. Gordon Charitable Remainder Unitrust.

February 13, 2014 – With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms.

January 9, 2014 – Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products.

November 13, 2012 – Cellax™, invented by OICR researchers, is a drug-polymer conjugate based on the proprietary NanoCMC™ technology.

June 7, 2012 – OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma.

January 30, 2012 – Investors in the Series A round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario Capital Growth Corporation through its Emerging Technologies Fund.

May 3, 0206 – Triphase is expanding its current collaboration with Celgene in the development of marizomib for the potential treatment of malignant gliomas.